These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23298879)

  • 1. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.
    Abel GA; Koreth J
    Curr Opin Hematol; 2013 Mar; 20(2):150-6. PubMed ID: 23298879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
    Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
    J Clin Oncol; 2013 Jul; 31(21):2662-70. PubMed ID: 23797000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
    Servais S; Baron F; Beguin Y
    Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Estey E; de Lima M; Tibes R; Pierce S; Kantarjian H; Champlin R; Giralt S
    Blood; 2007 Feb; 109(4):1395-400. PubMed ID: 17038533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New progress of study on hematopoietic stem cell transplantation for myelodysplastic syndromes].
    Wu B; Wei Y; Zhang Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):510-3. PubMed ID: 22541129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: improved outcomes for de novo disease.
    Andolina JR; Kletzel M; Tse WT; Jacobsohn DA; Duerst RE; Schneiderman J; Helenowski I; Rademaker A; Chaudhury S
    Pediatr Transplant; 2011 May; 15(3):334-43. PubMed ID: 21492354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?
    El-Jawahri A; Kim HT; Steensma DP; Cronin AM; Stone RM; Watts CD; Chen YB; Cutler CS; Soiffer RJ; Abel GA
    Bone Marrow Transplant; 2016 Aug; 51(8):1121-6. PubMed ID: 26999469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
    Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ
    Br J Haematol; 2006 Oct; 135(2):201-9. PubMed ID: 16939494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation for myelodysplastic syndrome.
    Parmar S; de Lima M
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S37-44. PubMed ID: 19857589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.
    Warlick ED
    Curr Opin Oncol; 2010 Mar; 22(2):150-4. PubMed ID: 20010295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities.
    Lee SE; Kim YJ; Yahng SA; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Eur J Haematol; 2011 Dec; 87(6):510-20. PubMed ID: 21883477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome.
    de Witte T; Oosterveld M; Muus P
    Blood Rev; 2007 Jan; 21(1):49-59. PubMed ID: 16822600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.